Industry Restructuring & Inorganic Growth Through an Era of Chronic Oversupply (World Chemical Forum Speech September 10, 2024)

Jonathan Choi2024-10-14T18:41:13+00:00September 10th, 2024|Featured, Our Publications|

Young & Partners shares their thoughts and analysis of the global oversupply and uncertainties that have impacted the chemical markets. The presentation addresses the era of chronic oversupply, strategic assessments, M&A market conditions, and Strategic and M&A alternatives.

Chemical Debt Financing Rebounds (ICIS Chemical Business September 6 – September 12, 2024)

Jonathan Choi2024-10-15T15:22:50+00:00September 6th, 2024|Featured, Our Publications|

Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have rebounded chemical debt financings and the outlook for 2024.

Chemical M&A Retreats Further (ICIS Chemical Business August 31 – September 5, 2024)

Jonathan Choi2024-09-17T14:15:04+00:00September 5th, 2024|Featured, Our Publications|

Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed chemical M&A and the outlook for 2024.

Chemical Financing Activity Mixed (ICIS Chemical Business May 31 – June 6, 2024)

Jonathan Choi2024-06-20T16:34:06+00:00May 31st, 2024|Featured, Our Publications|

Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed chemical financing and the outlook for 2024.

Chemical M&A Market Retreats (ICIS Chemical Business May 17 – May 23, 2024)

Jonathan Choi2024-05-22T20:35:28+00:00May 17th, 2024|Featured, Our Publications|

Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed M&A and the outlook for 2024.

Young & Partners Chemical Financing: Reflections on 2023 and Outlook (March 2024)

Jonathan Choi2024-05-22T20:36:59+00:00March 26th, 2024|Featured, Our Publications|

Proprietary data and analysis of chemical financing trends in 2023 and the current outlook.

Biopharma Industry Business Review and Outlook (Pharmaceutical Executive, March 2024)

Jonathan Choi2024-03-20T17:34:33+00:00March 20th, 2024|Featured, Our Publications|

Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in 2023, and the outlook for 2024.

Young & Partners 2023 Chemical Conference: Speakers Roundtable- What Does the Future Hold?

Jonathan Choi2023-12-28T14:56:09+00:00November 29th, 2023|Our Broadcasts|

Peter Young, Young & Partners Mathias Zachert, CEO of Lanxess Kamal Navarthy, President of Reliance Dewey Johnson, SVP Chemical Market Analytics

2023 Chemical Conference Speaker Summary

Jonathan Choi2023-12-28T15:05:53+00:00November 29th, 2023|Chemical Conferences|

Young & Partners 2023 Chemical Conference: Dewey Johnson: The Dramatic Energy Industry Changes and Their Impact on Chemicals

Jonathan Choi2023-12-28T15:08:48+00:00November 29th, 2023|Our Broadcasts|

Dewey Johnson, SVP Dow Jones, Global Lead Chemical Market Analytics

Young & Partners 2023 Chemical Conference: Kamal Nanavaty: Perspectives on the Asian Chemical Industry and Markets

Jonathan Choi2023-12-28T15:07:37+00:00November 29th, 2023|Our Broadcasts|

Kamal Nanavaty, President, Strategy Development, Reliance Industries Limited

Young & Partners 2023 Chemical Conference: Matthias Zachert Fireside Chat: Chemical Industry in Europe – Quo Vadis

Jonathan Choi2023-12-28T15:07:17+00:00November 29th, 2023|Our Broadcasts|

Matthias Zachert, Chairman of the Management Board, CEO, Lanxess AG

Young & Partners 2023 Pharmaceutical Executive Summit: Speakers Roundtable- What Does the Future Hold

Jonathan Choi2023-12-28T15:05:07+00:00November 9th, 2023|Our Broadcasts|

Doug Long, Vice President, Industry Relations, IQVIA Peter Stein, M.D., Director, Office of New Drugs, U.S. Food and Drug Administration Dr. Stephen P. Spielberg, M.D. PhD, Senior Adviser, Young & Partners; former Deputy Commissioner for Medical Products and Tobacco, U.S. Food and Drug Administration Eli Weinberg, Partner, Bain & Company Life Sciences

Young & Partners 2023 Pharmaceutical Executive Summit: Disruptive Innovation, Research, Manufacturing and AI

Jonathan Choi2023-12-28T15:06:22+00:00November 9th, 2023|Our Broadcasts|

Dr. Stephen P. Spielberg, M.D. PhD, Senior Adviser, Young & Partners; former Deputy Commissioner for Medical Products and Tobacco, FDA Eli Weinberg, Partner, Bain & Company Life Sciences.

Young & Partners 2023 Pharmaceutical Executive Summit: Doug Long: The Pharmaceutical Market: Trends, Issues and Outlook

Jonathan Choi2023-12-28T15:06:38+00:00November 9th, 2023|Our Broadcasts|

Doug Long, Vice President, IQVIA Holdings Inc.

Young & Partners 2023 Pharmaceutical Executive Summit: Peter Stein Fireside Chat: Brave New World- Adapting to Change

Jonathan Choi2023-12-28T15:06:45+00:00November 9th, 2023|Our Broadcasts|

Dr. Peter Stein, Director, Office of New Drugs, U.S. Food and Drug Administration

2023 Pharmaceutical Conference Speaker Summary

Jonathan Choi2023-12-28T14:50:46+00:00November 9th, 2023|Life Science Conferences|

Young & Partners Forum: A Look Into the Future (October 17, 2023)

Jonathan Choi2023-10-19T13:28:48+00:00October 17th, 2023|Our Broadcasts|

Robert Westervelt, Editor in Chief, Chemical Week Peter Young, CEO and Managing Partner, Young & Partners

Biopharma Market Review and Outlook (Pharmaceutical Executive, October 2023)

Jonathan Choi2023-10-16T14:00:23+00:00October 16th, 2023|Featured, Our Publications|

Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in the first half, and the outlook for 2023.

Young & Partners Forum: The Impact of AI on the Life Sciences Industry (September 18, 2023)

Jonathan Choi2023-09-18T20:03:42+00:00September 18th, 2023|Our Broadcasts|

Panelists: Dylan Reid, Partner, Zetta Ventures Eli Weinberg, Life Sciences Partner, Bain & Company Moderator: Peter Young, CEO and Managing Partner, Young & Partners